Suscribirse

Preexisting comorbidities shape the immune response associated with severe COVID-19 - 04/08/22

Doi : 10.1016/j.jaci.2022.05.019 
Stefanie Kreutmair, MD a, b, , Manuel Kauffmann, MSc a, , Susanne Unger, PhD a, , Florian Ingelfinger, PhD a, , Nicolás Gonzalo Núñez, PhD a, , Chiara Alberti, PhD a, Donatella De Feo, MD, PhD a, Sinduya Krishnarajah, PhD a, Ekaterina Friebel, PhD a, Can Ulutekin, MSc a, Sepideh Babaei, PhD c, Benjamin Gaborit, MD, PhD d, Mirjam Lutz a, Nicole Puertas Jurado a, Nisar P. Malek, MD c, e, Siri Göpel, MD c, f, Peter Rosenberger, MD g, Helene A. Häberle, MD g, Ikram Ayoub, MSc h, Sally Al-Hajj, PhD h, Manfred Claassen, PhD c, , Roland Liblau, MD, PhD h, , Guillaume Martin-Blondel, MD, PhD h, i, , Michael Bitzer, MD c, e, , Antoine Roquilly, MD, PhD d, , Burkhard Becher, PhD a, ,
a Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland 
b German Cancer Consortium and German Cancer Research Center, Heidelberg, Partner Site Freiburg, Freiburg, Germany 
c Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany 
e the Center for Personalized Medicine, Eberhard-Karls University, Tuebingen, Germany 
g the Department of Anesthesiology and Intensive Care Medicine, Eberhard-Karls University, Tuebingen, Germany 
d Université de Nantes, CHU Nantes, EA3826 Thérapeutiques Anti-Infectieuses, Institut de Recherche en Santé 2 Nantes Biotech, Service d’Anesthésie Réanimation chirurgicale, Hôtel Dieu, Nantes, France 
f the German Centre for Infection Research, Partner Site Tuebingen, Tuebingen, Germany 
h Toulouse Institute for Infectious and Inflammatory Diseases, Université de Toulouse, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Toulouse, France 
i Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France 

Corresponding author: Burchard Becher, PhD, Institute of Experimental Immunology, University of Zurich, Winterthurer Strasse 190, 8057 Zurich, Switzerland.Institute of Experimental ImmunologyUniversity of ZurichWinterthurer Strasse 190Zurich8057Switzerland∗∗Stefanie Kreutmair, MD, Institute of Experimental Immunology, University of Zurich, Winterthurer Strasse 190, 8057 Zurich, Switzerland.Institute of Experimental ImmunologyUniversity of ZurichWinterthurer Strasse 190Zurich8057Switzerland

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Comorbidities are risk factors for development of severe coronavirus disease 2019 (COVID-19). However, the extent to which an underlying comorbidity influences the immune response to severe acute respiratory syndrome coronavirus 2 remains unknown.

Objective

Our aim was to investigate the complex interrelations of comorbidities, the immune response, and patient outcome in COVID-19.

Methods

We used high-throughput, high-dimensional, single-cell mapping of peripheral blood leukocytes and algorithm-guided analysis.

Results

We discovered characteristic immune signatures associated not only with severe COVID-19 but also with the underlying medical condition. Different factors of the metabolic syndrome (obesity, hypertension, and diabetes) affected distinct immune populations, thereby additively increasing the immunodysregulatory effect when present in a single patient. Patients with disorders affecting the lung or heart, together with factors of metabolic syndrome, were clustered together, whereas immune disorder and chronic kidney disease displayed a distinct immune profile in COVID-19. In particular, severe acute respiratory syndrome coronavirus 2–infected patients with preexisting chronic kidney disease were characterized by the highest number of altered immune signatures of both lymphoid and myeloid immune branches. This overall major immune dysregulation could be the underlying mechanism for the estimated odds ratio of 16.3 for development of severe COVID-19 in this burdened cohort.

Conclusion

The combinatorial systematic analysis of the immune signatures, comorbidities, and outcomes of patients with COVID-19 has provided the mechanistic immunologic underpinnings of comorbidity-driven patient risk and uncovered comorbidity-driven immune signatures.

El texto completo de este artículo está disponible en PDF.

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Key words : COVID-19, SARS-CoV-2, immune response, spectral flow cytometry, comorbidity, metabolic syndrome, chronic kidney disease, heart disease, immune disorder, algorithm-guided analysis

Abbreviations used : ACE2, CKD, CM, COVID-19, DC, EM, HD, ID, LAD, NK, OR, PCA, SARS-CoV-2, TEMRA, T2DM, WHO


Esquema


 Supported by the Swiss National Science Foundation, Switzerland (grants 733 310030_170320, 310030_188450, and CRSII5_183478 to B.B, 31CA30_195883 [to S.K., M.C., M.B., and B.B.]), The LOOP Zurich, the Vontobel Foundation (to B.B.), the European Union’s Horizon 2020 Research and Innovation Program (grant 847782 [to B.B. and A.R.]), and the European Research Council (grant 882424 [to B.B.]), the Agence National de la Recherche and Region Pays de la Loire - Flash COVID-19:COVARDS project (to A.R.), the INSPIRE regional initiative (to R.L.), and the French Ministry of Health with the participation of the Groupement Interrégional de Recherche Clinique et d’Innovation Sud-Ouest Outre-Mer (PHRCI 2020 IMMUNOMARK-COV [to R.L. and G.M.-B.]). S. Kreutmair is the recipient of a postdoctoral fellowship of the Deutsche Forschungsgemeinschaft. N.G.N. is the recipient of a University Research Priority Program postdoctoral fellowship. F.I. received a PhD fellowship from the Studienstiftung des deutschen Volkes.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 150 - N° 2

P. 312-324 - août 2022 Regresar al número
Artículo precedente Artículo precedente
  • Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study
  • Max A. Seibold, Camille M. Moore, Jamie L. Everman, Blake J.M. Williams, James D. Nolin, Ana Fairbanks-Mahnke, Elizabeth G. Plender, Bhavika B. Patel, Samuel J. Arbes, Leonard B. Bacharier, Casper G. Bendixsen, Agustin Calatroni, Carlos A. Camargo, William D. Dupont, Glenn T. Furuta, Tebeb Gebretsadik, Rebecca S. Gruchalla, Ruchi S. Gupta, Gurjit K. Khurana Hershey, Liza Bronner Murrison, Daniel J. Jackson, Christine C. Johnson, Meyer Kattan, Andrew H. Liu, Stephanie J. Lussier, George T. O’Connor, Katherine Rivera-Spoljaric, Wanda Phipatanakul, Marc E. Rothenberg, Christine M. Seroogy, Stephen J. Teach, Edward M. Zoratti, Alkis Togias, Patricia C. Fulkerson, Tina V. Hartert, HEROS study team
| Artículo siguiente Artículo siguiente
  • Association of the gut microbiome and metabolome with wheeze frequency in childhood asthma
  • Kathleen Lee-Sarwar, Sandra Dedrick, Babak Momeni, Rachel S. Kelly, Robert S. Zeiger, George T. O’Connor, Megan T. Sandel, Leonard B. Bacharier, Avraham Beigelman, Nancy Laranjo, Diane R. Gold, Jessica Lasky-Su, Augusto A. Litonjua, Yang-Yu Liu, Scott T. Weiss

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.